Long-Term, Implantable Event Monitoring of Patients With Wild-Type Transthyretin Cardiac Amyloidosis: A Pilot Study.
作者信息
Abbasi Muhannad Aboud, El-Am Edward, Deshmukh Abhishek, Dispenzieri Angela, Grogan Martha, Ezzeddine Omar Abou, Lin Grace
机构信息
Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota.
Department of Hematology-Oncology, Mayo Clinic, Rochester, Minnesota.
出版信息
JACC CardioOncol. 2024 Feb 27;6(2):313-314. doi: 10.1016/j.jaccao.2024.01.005. eCollection 2024 Apr.
Abstract
摘要
相似文献
1
Long-Term, Implantable Event Monitoring of Patients With Wild-Type Transthyretin Cardiac Amyloidosis: A Pilot Study.
JACC CardioOncol. 2024 Feb 27;6(2):313-314. doi: 10.1016/j.jaccao.2024.01.005. eCollection 2024 Apr.
2
Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey.
JACC CardioOncol. 2021 Oct 19;3(4):537-546. doi: 10.1016/j.jaccao.2021.08.009. eCollection 2021 Oct.
3
Transthyretin Cardiac Amyloidosis in Older Adults: Optimizing Cardiac Imaging to the Corresponding Diagnostic and Management Goal.
Curr Cardiovasc Risk Rep. 2017 Jun;11. doi: 10.1007/s12170-017-0541-x. Epub 2017 Apr 25.
4
Pressure-volume relationships in patients with transthyretin (ATTR) cardiac amyloidosis secondary to V122I mutations and wild-type transthyretin: Transthyretin Cardiac Amyloid Study (TRACS).
Circ Heart Fail. 2011 Mar;4(2):121-8. doi: 10.1161/CIRCHEARTFAILURE.109.910455. Epub 2010 Dec 29.
5
Ventricular arrhythmia burden and implantable cardioverter-defibrillator outcomes in transthyretin cardiac amyloidosis.
Pacing Clin Electrophysiol. 2022 Apr;45(4):443-451. doi: 10.1111/pace.14458. Epub 2022 Mar 18.
6
Transthyretin Cardiac Amyloidosis.
Curr Cardiol Rep. 2017 Aug 24;19(10):97. doi: 10.1007/s11886-017-0911-5.
7
THAOS: gastrointestinal manifestations of transthyretin amyloidosis - common complications of a rare disease.
Orphanet J Rare Dis. 2014 Apr 27;9:61. doi: 10.1186/1750-1172-9-61.
8
Sex Differences in Wild-Type Transthyretin Amyloidosis: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS).
Cardiol Ther. 2022 Sep;11(3):393-405. doi: 10.1007/s40119-022-00265-7. Epub 2022 May 18.
9
Non-Val30Met mutation, septal hypertrophy, and cardiac denervation in patients with mutant transthyretin amyloidosis.
ESC Heart Fail. 2019 Feb;6(1):122-130. doi: 10.1002/ehf2.12361. Epub 2018 Oct 4.
10
Prognostic impact of light-chain and transthyretin-related categories in cardiac amyloidosis: A systematic review and meta-analysis.
Hellenic J Cardiol. 2019 Nov-Dec;60(6):375-383. doi: 10.1016/j.hjc.2019.01.015. Epub 2019 Feb 8.
本文引用的文献
1
Electrophysiological Manifestations of Cardiac Amyloidosis: State-of-the-Art Review.
JACC CardioOncol. 2021 Oct 19;3(4):506-515. doi: 10.1016/j.jaccao.2021.07.010. eCollection 2021 Oct.
2
Diagnosis, Prognosis, and Therapy of Transthyretin Amyloidosis.
J Am Coll Cardiol. 2015 Dec 1;66(21):2451-2466. doi: 10.1016/j.jacc.2015.09.075.
3
Electrophysiologic assessment of conduction abnormalities and atrial arrhythmias associated with amyloid cardiomyopathy.
Heart Rhythm. 2016 Feb;13(2):383-90. doi: 10.1016/j.hrthm.2015.09.016. Epub 2015 Sep 21.
4
A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis.
Eur Heart J. 2015 May 7;36(18):1098-105. doi: 10.1093/eurheartj/ehu506. Epub 2014 Dec 29.
5
Implantable cardioverter defibrillators in patients with cardiac amyloidosis.
J Cardiovasc Electrophysiol. 2013 Jul;24(7):793-8. doi: 10.1111/jce.12123. Epub 2013 Mar 14.
Zotero 插件